New York-based pharmaceutical giant Bristol-Myers Squibb has reportedly signed a deal worth $438 million with Reckitt Benckiser, a personal health products company based in the UK. According to reports, the deal will last for three years an includes an agreement to a $44 million option fee, giving Reckitt the option of buying Bristol-Myers brands at the end of the three years. The contract gives Bristol-Myers control over Reckitt manufacturing and, in turn, allows Reckitt to sell Bristol-Myers medicines throughout Latin America, especially Mexico and Brazil. Mexico and Brazil antitrust authorities may review the deal, however.
Featured News
Live Nation Pushes Back on States’ Renewed Bid for DOJ Settlement Records
Oct 4, 2026 by
CPI
California Subpoenas OpenAI as Scrutiny of AI Cybersecurity Risks Grows
Oct 4, 2026 by
CPI
Thomson Reuters Faces Antitrust Suit Over $650 Million Casetext Acquisition
Oct 4, 2026 by
CPI
Sandoz Agrees to $400 Million Deal to Resolve States’ Generic-Drug Antitrust Case
Oct 4, 2026 by
CPI
Amazon e-Book Buyers Move Closer to Class Certification in Antitrust Case
Oct 4, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – National Security
Sep 22, 2026 by
CPI
National Security in U.S. Antitrust Enforcement: Toward a More Disciplined Framework
Sep 22, 2026 by
Rod Rosenstein & Timothy Finley
The Department of War’s M&A Review Guidance: What Companies in the Defense Industry Need to Know
Sep 22, 2026 by
Eric Stocking & Paul Ney
National Security, Resilience and the Boundaries of Merger Control
Sep 22, 2026 by
Beatriz Marques
National Security and Competition: Building Resilient Telecommunications Networks
Sep 22, 2026 by
Roslyn Layton